Revolution Medicines, Inc.: retained earnings or deficit
Retained earnings or deficit for Revolution Medicines, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Revolution Medicines, Inc. financial histories
What this measure means
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
Exact concept: us-gaap:RetainedEarningsAccumulatedDeficit. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2019-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | -2,869,102,000 | USD | 2026-02-25 | 10-K · 0001193125-26-071563 |
| At date | 2024-12-31 | -1,737,801,000 | USD | 2026-02-25 | 10-K · 0001193125-26-071563 |
| At date | 2023-12-31 | -1,137,708,000 | USD | 2025-02-26 | 10-K · 0000950170-25-027736 |
| At date | 2022-12-31 | -701,341,000 | USD | 2024-02-26 | 10-K · 0000950170-24-020145 |
| At date | 2021-12-31 | -452,636,000 | USD | 2023-02-27 | 10-K · 0000950170-23-004645 |
| At date | 2020-12-31 | -265,545,000 | USD | 2022-02-28 | 10-K · 0000950170-22-002297 |
| At date | 2019-12-31 | -157,386,000 | USD | 2021-03-02 | 10-K · 0001564590-21-010276 |
Related financial histories
- Revolution Medicines, Inc.: total assets
- Revolution Medicines, Inc.: total liabilities
- Revolution Medicines, Inc.: stockholders equity
- Revolution Medicines, Inc.: cash and cash equivalents
- Revolution Medicines, Inc.: net income or loss
- Revolution Medicines, Inc.: operating cash flow
- Revolution Medicines, Inc.: capital expenditure payments
- Revolution Medicines, Inc.: contract revenue excluding tax
- Revolution Medicines, Inc.: financing cash flow
- Revolution Medicines, Inc.: investing cash flow
- Revolution Medicines, Inc.: basic weighted-average shares
- Revolution Medicines, Inc.: diluted weighted-average shares
- Revolution Medicines, Inc.: basic earnings per share
- Revolution Medicines, Inc.: diluted earnings per share
- Revolution Medicines, Inc.: income tax expense or benefit
- Revolution Medicines, Inc.: net property, plant and equipment
- Revolution Medicines, Inc.: share-based compensation expense
- Revolution Medicines, Inc.: operating income or loss
- Revolution Medicines, Inc.: current assets
- Revolution Medicines, Inc.: interest expense
- Revolution Medicines, Inc.: current liabilities
- Revolution Medicines, Inc.: current accounts payable
- Revolution Medicines, Inc.: net finite-lived intangible assets
- Revolution Medicines, Inc.: operating expenses
- Revolution Medicines, Inc.: research and development expense
Inspect the source
- Entity
- Revolution Medicines, Inc. / CIK 0001628171
- Captured
- 2026-09-21T17:21:03.080Z
- SEC response SHA-256
69f07a87145d10129e74be1cc27db6c66afcf8ae4c3561e233c6fe360acd69fc
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001628171.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))